2 completed, 1 recruiting, 1 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
Follow Gray Zone Lymphoma: new trials by email Literature Review of Gray Zone Lymphoma trials Research Report on Gray Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma PD-1 inhibitor +ICE - Gray Zone Lymphoma, Relapse/Recurrence | Phase 2 | Unknown | Zhejiang Cancer Hospital | 20 | 2021-05-01 | 2021-04-27 |
| Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Everolimus, Rituximab - CD20+, B-cell Lymphomas, Mantle Cell Lymphoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 56 | 2012-09-01 | 2021-10-26 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 348 | 1993-05-08 | 2025-06-22 |
Burkitt Lymphoma (1) · Hodgkin Disease (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Recurrence (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2) · DNA Virus Infections (1) · Disease Attributes (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Infections (1)
Etoposide (2) · Rituximab (2) · Biopsy (1) · Carboplatin (1) · Cyclophosphamide (1) · Dioctyl Sulfosuccinic Acid (1) · Doxorubicin (1) · Everolimus (1) · Lactulose (1) · Laparotomy (1) · Magnetic Resonance Imaging (1) · Omeprazole (1) · Ondansetron (1) · Positron-Emission Tomography (1) · Prednisone (1)
National Cancer Institute (NCI) (1) · Seda S. Tolu (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Zhejiang Cancer Hospital (1)
United States (3)
Cong Li (1) · Douglas Gladstone, MD (1) · Mark J Roschewski, M.D. (1) · Seda Tolu, MD (1)
PMID 23574119, PMID 24224624, PMID 25024303, PMID 29234922, PMID 29748435, PMID 30125215, PMID 34432874, PMID 35882475